Use of Pharmacogenomics and Biomarkers in the Development of New Drugs for Alzheimer Disease in Japan

Clinical Therapeutics

Volumn 37, Issue 8, 2015, Pages 1627-1631

  Otsubo, Yasuto ^a  

^a Japan Ministry of Health Labour and Welfare   (Japan)

Author keywords

Alzheimer disease; biomarkers; Japan; pharmacogenomics

Indexed keywords

ALECTINIB; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; CEREBROSPINAL FLUID PI; CRIZOTINIB; MOGAMULIZUMAB; NEW DRUG; TAU PROTEIN; UNCLASSIFIED DRUG; NOOTROPIC AGENT; PHARMACOLOGICAL BIOMARKER;

ALZHEIMER DISEASE; DIAGNOSIS; DRUG DESIGN; DRUG EFFICACY; DRUG INDUSTRY; DRUG SCREENING; JAPAN; PHARMACOGENOMICS; PRACTICE GUIDELINE; PROTEIN CEREBROSPINAL FLUID LEVEL; REVIEW; RISK BENEFIT ANALYSIS; BLOOD; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; HUMAN; PHARMACOGENETICS;

ALZHEIMER DISEASE; BIOMARKERS, PHARMACOLOGICAL; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; JAPAN; NOOTROPIC AGENTS; PHARMACOGENETICS;

EID: 84940590619     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.04.010     Document Type: Note

References (19)

1. Pharmaceuticals and Medical Devices Agency. Memantine hydrochloride review report [in Japanese]. [cited April 1, 2015]; http://www.info.pmda.go.jp/shinyaku/P201100018/43057400-22300AMX00423-A100-2.pdf (January 2011).
2. Pharmaceuticals and Medical Devices Agency. Galantamine hydrobromide review report [in Japanese]. [cited April 1, 2015]; http://www.info.pmda.go.jp/shinyaku/P201100024/80015500-23000AMX00426-A100-1.pdf (January 2011).
3. Pharmaceuticals and Medical Devices Agency. Rivastigmine review report [in Japanese]. [cited April 1, 2015]; http://www.info.pmda.go.jp/shinyaku/P201100075/18018800-22300AMX00529000-A100-1.pdf (April 2011).
4. Japan Health Sciences Foundation; Report on medical needs in 60 diseases and new medical needs [cited April 1, 2015]; http://www.jhsf.or.jp/paper/report/report-201401.pdf.
5. S. Salloway, R. Sperling, S. Gilman, and et al. Bapineuzumab 201 Clinical Trial Investigators. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 73 2009 2061 2070
6. A study of gantenerumab in patients with mild Alzheimer disease. [cited April 1, 2015]; https://clinicaltrials.gov/ct2/show/NCT02051608?term=Gantenerumab&rank=3.
7. Progress of mild Alzheimer's disease in participants on solanezumab versus placebo (EXPEDITION 3). [cited April 1, 2015]; https://clinicaltrials.gov/ct2/show/NCT01900665?term=solanezumab&rank=1.
8. University of Tokyo Hospital. Issues to consider in the clinical evaluation and development of drugs for Alzheimer's disease (interim report) [in Japanese]. [cited April 1, 2015]; http://www.pmda.go.jp/files/000164606.pdf. (2013).
9. US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: Alzheimer's Disease: Developing drugs for the treatment of early stage disease draft guidance. [cited April 1, 2015]; http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm338287.pdf. (2013).
10. ICH E16 guideline; Biomarkers related to drug or biotechnology product development: context, structure and format of qualification submissions. [cited April 1, 2015]; http://www.pmda.go.jp/files/000156251.pdf. (2010).
11. F.A. Thiers, A.J. Sinskey, and E.R. Berndt Trends in the globalization of clinical trials Nat Rev Drug Discov 7 2008 13 14
12. F. Dieterle, F. Sistare, F. Goodsaid, and et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium Nat Biotech 28 2010 455 462
13. Pharmaceuticals and Medical Devices Agency. Record of the consultation on pharmacogenomics/biomarkers for drug-induced kidney injury biomarkers. [cited April 1, 2015]; http://www.pmda.go.jp/files/000160006.pdf. (2010).
14. M. Isaac, S. Vamvakas, E. Abadie, and et al. Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden - Regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials Eur Neuropsychopharmacol 21 2011 781 788
15. European Medicines Agency. Qualification opinion of low hippocampal volume (atrophy) by MRI for use in clinical trials for regulatory purpose - in pre-dementia stage of Alzheimer's disease (EMA/CHMP/SAWP/809208/2011). [cited April 1, 2015]; http://www.ema.europa.eu/docs/en-GB/document-library/Regulatory-and-procedural-guideline/2011/12/WC500118737.pdf. (2010).
16. European Medicines Agency. Qualification opinion of Alzheimer's disease novel methodologies/biomarkers for PET amyloid imaging (positive/negative) as a biomarker for enrichment, for use in regulatory clinical trials in predementia Alzheimer's disease (EMA/CHMP/SAWP/892998/2011). [cited April 1, 2015]; http://www.ema.europa.eu/docs/en-GB/document-library/Regulatory-and-procedural-guideline/2012/04/WC500125018.pdf. (2011).
17. Ministry of Health Labour and Welfare. Notification on approval application for in vitro companion diagnostics and corresponding therapeutic products (Notification no. 0701-10, Evaluation and Licensing Division, Pharmaceuticals and Food Safety Bureau). [cited April 1, 2015]; http://www.pmda.go.jp/files/000153914.pdf. (2013).
18. Ministry of Health Labour and Welfare. Technical guidance on development of in vitro companion diagnostics and corresponding therapeutic products (Administrative Notice, Evaluation and Licensing Division, Pharmaceuticals and Food Safety Bureau). [cited April 1, 2015]; http://www.pmda.go.jp/files/000153149.pdf. (2013).
19. Y. Otsubo, A. Ishiguro, and Y. Uyama Regulatory perspective on remaining challenges for utilization of pharmacogenomics - guided drug developments Pharmacogenomics 14 2013 195 203